BG106554A - Ген prv-1 и неговото приложение - Google Patents

Ген prv-1 и неговото приложение Download PDF

Info

Publication number: BG106554A
Authority: BG; Bulgaria
Prior art keywords: amino acids; sequence; polypeptide; prv; cells
Prior art date: 1999-09-30

Application number

BG106554A

Other languages

Bulgarian (bg)

English (en)

Inventor

Heike Pahl

Original Assignee

Universitatsklinikum Freiburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2002-03-27

Publication date

2003-01-31

2002-03-27 Application filed by Universitatsklinikum Freiburg filed Critical Universitatsklinikum Freiburg

2003-01-31 Publication of BG106554A publication Critical patent/BG106554A/bg

Links

108090000623 proteins and genes Proteins 0.000 title abstract description 60
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 67
229920001184 polypeptide Polymers 0.000 claims abstract description 66
150000001413 amino acids Chemical class 0.000 claims description 117
239000012634 fragment Substances 0.000 claims description 35
108091033319 polynucleotide Proteins 0.000 claims description 20
102000040430 polynucleotide Human genes 0.000 claims description 20
239000002157 polynucleotide Substances 0.000 claims description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 13
238000011282 treatment Methods 0.000 claims description 13
240000006711 Pistacia vera Species 0.000 claims description 12
239000003102 growth factor Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
210000001185 bone marrow Anatomy 0.000 claims description 8
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
208000014767 Myeloproliferative disease Diseases 0.000 claims description 6
230000010261 cell growth Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
230000002062 proliferating effect Effects 0.000 claims description 6
208000032839 leukemia Diseases 0.000 claims description 4
208000032027 Essential Thrombocythemia Diseases 0.000 claims description 3
206010025323 Lymphomas Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
206010033661 Pancytopenia Diseases 0.000 claims description 3
239000000824 cytostatic agent Substances 0.000 claims description 3
206010028537 myelofibrosis Diseases 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims 12
238000000338 in vitro Methods 0.000 claims 1
239000002773 nucleotide Substances 0.000 abstract description 24
125000003729 nucleotide group Chemical group 0.000 abstract description 24
238000000034 method Methods 0.000 abstract description 21
108020004999 messenger RNA Proteins 0.000 abstract description 4
102100024209 CD177 antigen Human genes 0.000 abstract 1
101000980845 Homo sapiens CD177 antigen Proteins 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 89
102000004169 proteins and genes Human genes 0.000 description 31
235000018102 proteins Nutrition 0.000 description 30
239000000203 mixture Substances 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 21
229940024606 amino acid Drugs 0.000 description 20
210000003714 granulocyte Anatomy 0.000 description 19
238000002474 experimental method Methods 0.000 description 17
108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
230000003394 haemopoietic effect Effects 0.000 description 15
239000013598 vector Substances 0.000 description 15
239000002609 medium Substances 0.000 description 14
230000014509 gene expression Effects 0.000 description 13
241001430294 unidentified retrovirus Species 0.000 description 13
210000003013 erythroid precursor cell Anatomy 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
239000000523 sample Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
230000001605 fetal effect Effects 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
108020004414 DNA Proteins 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000000925 erythroid effect Effects 0.000 description 6
239000005090 green fluorescent protein Substances 0.000 description 6
UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 5
102000003951 Erythropoietin Human genes 0.000 description 5
108090000394 Erythropoietin Proteins 0.000 description 5
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
229940105423 erythropoietin Drugs 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
235000010981 methylcellulose Nutrition 0.000 description 5
208000037244 polycythemia vera Diseases 0.000 description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
239000002243 precursor Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
239000006143 cell culture medium Substances 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
210000005087 mononuclear cell Anatomy 0.000 description 4
239000008188 pellet Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003757 reverse transcription PCR Methods 0.000 description 4
235000002639 sodium chloride Nutrition 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
108020004705 Codon Proteins 0.000 description 3
208000017733 acquired polycythemia vera Diseases 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
239000000284 extract Substances 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000016507 interphase Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000010186 staining Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
108091026890 Coding region Proteins 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
229920001917 Ficoll Polymers 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
208000005485 Thrombocytosis Diseases 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000008274 jelly Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000007447 staining method Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018690 Granulocytosis Diseases 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010013377 Retroviridae Proteins Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000035558 fertility Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
210000000777 hematopoietic system Anatomy 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000009533 lab test Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
-1 secondary antibodies Substances 0.000 description 1
208000013213 secondary polycythemia Diseases 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000013518 transcription Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

BG106554A 1999-09-30 2002-03-27 Ген prv-1 и неговото приложение BG106554A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19947010A DE19947010A1 (de)	1999-09-30	1999-09-30	Das Gen PRV-1 und dessen Verwendung
PCT/EP2000/009594 WO2001023554A1 (de)	1999-09-30	2000-09-29	Das gen prv-1 und dessen verwendung

Publications (1)

Publication Number	Publication Date
BG106554A true BG106554A (bg)	2003-01-31

Family

ID=7923937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106554A BG106554A (bg)	1999-09-30	2002-03-27	Ген prv-1 и неговото приложение

Country Status (21)

Country	Link
EP (1)	EP1220920A1 (cs)
JP (1)	JP2003510077A (cs)
KR (1)	KR20020047191A (cs)
CN (1)	CN1377408A (cs)
AU (1)	AU1132401A (cs)
BG (1)	BG106554A (cs)
BR (1)	BR0014444A (cs)
CA (1)	CA2387702A1 (cs)
CZ (1)	CZ20021094A3 (cs)
DE (1)	DE19947010A1 (cs)
EA (1)	EA200200286A1 (cs)
EE (1)	EE200200168A (cs)
HR (1)	HRP20020269A2 (cs)
HU (1)	HUP0203080A2 (cs)
IL (1)	IL148770A0 (cs)
MX (1)	MXPA02002800A (cs)
NO (1)	NO20021498L (cs)
PL (1)	PL354184A1 (cs)
SK (1)	SK4262002A3 (cs)
WO (1)	WO2001023554A1 (cs)
ZA (1)	ZA200202379B (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL158599A0 (en) *	2003-10-26	2004-05-12	Yeda Res & Dev	Methods of modulating hematopoiesis
WO2013177062A2 (en)	2012-05-21	2013-11-28	Genentech, Inc.	Methods for improving safety of blood-brain barrier transport
CN111094547B (zh) *	2017-06-14	2024-02-09	德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司）	用于纯化源自人胚胎干细胞的内胚层和胰腺内胚层细胞的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2289118A1 (en) *	1997-05-06	1998-11-12	Zymogenetics, Inc.	Novel tumor antigens
CA2328895A1 (en) *	1998-06-02	1999-12-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE19849044A1 (de) *	1998-10-23	2000-04-27	Univ Ludwigs Albert	Das Gen PRV-1 und dessen Verwendung
CA2348757A1 (en) *	1998-12-16	2000-06-22	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same

1999
- 1999-09-30 DE DE19947010A patent/DE19947010A1/de not_active Withdrawn
2000
- 2000-09-29 CA CA002387702A patent/CA2387702A1/en not_active Abandoned
- 2000-09-29 AU AU11324/01A patent/AU1132401A/en not_active Abandoned
- 2000-09-29 BR BR0014444-4A patent/BR0014444A/pt not_active Application Discontinuation
- 2000-09-29 IL IL14877000A patent/IL148770A0/xx unknown
- 2000-09-29 EA EA200200286A patent/EA200200286A1/ru unknown
- 2000-09-29 EE EEP200200168A patent/EE200200168A/xx unknown
- 2000-09-29 KR KR1020027004095A patent/KR20020047191A/ko not_active Withdrawn
- 2000-09-29 CN CN00813580A patent/CN1377408A/zh active Pending
- 2000-09-29 WO PCT/EP2000/009594 patent/WO2001023554A1/de not_active Ceased
- 2000-09-29 JP JP2001526936A patent/JP2003510077A/ja active Pending
- 2000-09-29 CZ CZ20021094A patent/CZ20021094A3/cs unknown
- 2000-09-29 HR HR20020269A patent/HRP20020269A2/hr not_active Application Discontinuation
- 2000-09-29 MX MXPA02002800A patent/MXPA02002800A/es unknown
- 2000-09-29 EP EP00972665A patent/EP1220920A1/de not_active Withdrawn
- 2000-09-29 HU HU0203080A patent/HUP0203080A2/hu unknown
- 2000-09-29 PL PL00354184A patent/PL354184A1/xx not_active IP Right Cessation
- 2000-09-29 SK SK426-2002A patent/SK4262002A3/sk unknown
2002
- 2002-03-25 ZA ZA200202379A patent/ZA200202379B/en unknown
- 2002-03-26 NO NO20021498A patent/NO20021498L/no not_active Application Discontinuation
- 2002-03-27 BG BG106554A patent/BG106554A/bg unknown

Also Published As

Publication number	Publication date
ZA200202379B (en)	2003-10-29
MXPA02002800A (es)	2002-07-22
CN1377408A (zh)	2002-10-30
NO20021498D0 (no)	2002-03-26
KR20020047191A (ko)	2002-06-21
NO20021498L (no)	2002-05-23
WO2001023554A1 (de)	2001-04-05
EE200200168A (et)	2003-04-15
DE19947010A1 (de)	2001-04-05
PL354184A1 (en)	2003-12-29
AU1132401A (en)	2001-04-30
CZ20021094A3 (cs)	2002-06-12
IL148770A0 (en)	2002-09-12
EP1220920A1 (de)	2002-07-10
JP2003510077A (ja)	2003-03-18
CA2387702A1 (en)	2001-04-05
HUP0203080A2 (hu)	2002-12-28
HRP20020269A2 (en)	2003-06-30
BR0014444A (pt)	2002-06-11
EA200200286A1 (ru)	2002-12-26
SK4262002A3 (en)	2002-09-10

Publication	Publication Date	Title
JP2002516103A (ja)	2002-06-04	インターロイキン２１およびインターロイキン２２
JP2001524814A (ja)	2001-12-04	２８種類のヒト分泌タンパク質
JPH07505139A (ja)	1995-06-08	肝成長因子レセプター
US5858701A (en)	1999-01-12	DNA encoding an insulin receptor substrate
CN102134275B (zh)	2013-12-04	表皮生长因子受体变异体
BG106554A (bg)	2003-01-31	Ген prv-1 и неговото приложение
TW201200151A (en)	2012-01-01	Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
CN110713544B (zh)	2023-05-16	融合基因plekha6-ntrk3及其在lch中的应用
US6686153B1 (en)	2004-02-03	PRV-1 gene and the use thereof
WO2012048667A1 (zh)	2012-04-19	表皮生长因子受体的外显子缺失变异体
JP2005505252A (ja)	2005-02-24	低酸素症誘導因子及び脈管形成を誘導するため及び筋肉機能を改善するためのそれらの使用
JP2002534112A (ja)	2002-10-15	骨髄特異的タンパク質
이현채	2017	The Role of Adenylyl Cyclase-Associated Protein1 (CAP1) in Transendothelial Migration of Monocytes to Promote Chronic Inflammation
CN101289504A (zh)	2008-10-22	骨髓再生调控蛋白brrg-1、其编码基因及其应用
CN101289505A (zh)	2008-10-22	骨髓再生调控蛋白brrg-2、其编码基因及其应用